All 1 tracked stories fall under one category: pharma. DarioHealth Corp. is most often covered alongside Ameluz, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about DarioHealth Corp.
All 1 tracked stories fall under one category: pharma. DarioHealth Corp. is most often covered alongside Ameluz, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. Their average consequence score of 5 runs below the beat's 6 for that window. DarioHealth Corp. appears in 1 tracked Biotech story from March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering DarioHealth Corp.. Shared-story counts are live from our verified record — not editorial picks.
Biofrontera and DarioHealth reported Q4 2025 results that underscore a strategic shift toward high-margin clinical and enterprise markets. Both companies are prioritizing a path to profitability through disciplined cost management and the expansion of recurring revenue streams in dermatology and digital chronic care.
DarioHealth Corp. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.